Stemirna Therapeutics, Once a Leading mRNA Developer in China, Enters Bankruptcy Proceedings
Stemirna Therapeutics Co., Ltd, a one-time leading mRNA developer in China, has officially commenced bankruptcy...
Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders
Novo Nordisk (NYSE: NVO) has escalated its legal battles in the healthcare sector by filing...
AstraZeneca and Daiichi Sankyo’s Enhertu Receives Fourth Indication Approval in China
AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568)’s co-developed antibody drug conjugate (ADC), Enhertu (trastuzumab...
BMS’s Dual Immunotherapy Achieves Global First Approval for MSI-H/dMMR CRC in China
On October 14, 2024, Bristol-Myers Squibb (BMS, NYSE: BMY) announced that the National Medical Products...
Sichuan Biokin Pharmaceutical Gets FDA Approval for CD33-Targeting ADC in Acute Myeloid Leukemia
Sichuan Biokin Pharmaceutical Co., Ltd, a Chinese pharmaceutical company listed on the Shanghai Stock Exchange...
iRegene Therapeutics Secures Over USD 14 Million in Series B Financing to Advance Cell Therapies
iRegene Therapeutics, a Wuhan-based biotechnology company specializing in the development of AI-enhanced chemically induced cell...
BrightGene’s BGM0504 Shows Promise in Phase II Obesity Study Without Diabetes
BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166), a Chinese biopharmaceutical company, has announced positive results...
Dizal Pharmaceutical’s Sunvozertinib Earns Breakthrough Designation for NSCLC from China’s NMPA
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a biopharmaceutical company based in China, has announced that...
NMPA Sets Forthcoming Guidelines for Domestic Drug Refiling Procedures
The National Medical Products Administration (NMPA) has issued a notification outlining the requirements for the...
Huawei Partners with Medical University Hospital to Boost Healthcare Innovation
The Affiliated Hospital of Xuzhou Medical University has entered into a comprehensive partnership with Huawei...
Reforgene Medicine’s Gene Editing Therapy RM-101 Clears IND Hurdle for Usher Syndrome Treatment
Reforgene Medicine, a pioneer in gene editing therapy based in Guangzhou, has secured Investigational New...
Akeso Biopharma Secures USD 250 Million in Share Placement, Bolstering Drug Development War chest
Akeso Biopharma (HKG: 9926), a biopharmaceutical company based in China, has declared the successful completion...
Jiangsu Hengrui’s RGL-193 Receives NMPA Greenlight for Parkinson’s Disease Clinical Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd, a leading pharmaceutical company based in China and listed as...
Novartis’s Brolucizumab Accepted for Review by China’s CDE for Potential DME Treatment
The Center for Drug Evaluation (CDE) has indicated that Novartis (NYSE: NVS), the Swiss pharmaceutical...
Pfizer’s Talzenna Combo Shows Improved Survival in mCRPC Patients, According to TALAPRO-2 Study
Pfizer Inc. (NYSE: PFE) has announced positive topline results regarding overall survival (OS) in the...
Teva Pharmaceutical Reaches Settlement with DOJ Over Alleged Kickbacks and Price-Fixing
Teva Pharmaceutical Industries Ltd (NYSE: TEVA), headquartered in Israel, has entered into a settlement agreement...
CSPC Pharma Initiates Phase III Trial for JMT101 in First-Line EGFR-Positive NSCLC Treatment
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has initiated...
KangaBio’s KGX101 Receives NMPA Approval for Clinical Trial in China
KangaBio, a biopharmaceutical company based in Shanghai, has announced that its investigational new drug (IND)...
Johnson & Johnson’s KLK2-CD3 Bispecific Antibody JNJ-78278343 Advances in Prostate Cancer Clinical Trials
JNJ-78278343, a KLK2-CD3 bispecific antibody, is currently in Phase I clinical trials globally. According to...
Merck KGaA’s Pergoveris Treatment Expands Access to Advanced Reproductive Care in Greater Bay Area
Merck KGaA (MRK, NYSE: MRK) , a leading science and technology company based in Germany,...